Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Belumosudil Oral Suspension vs Tablet in Healthy Adult Males
NCT07726914Phase 1Not yet recruiting
- Sponsor
- Sanofi
- Start
- Aug 2026
- Primary completion
- Sep 2026
01
Overview
Phase 1, randomised, open-label trial of belumosudil in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Sanofi. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration at Day 3 and Maximum Observed Plasma Concentration at Day 3. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT07726914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07726914.